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Carcinoma of the prostate is the second most common cause
of cancer in men and its incidence has virtually doubled over
the last 30 years. This increase is far in excess of that
expected to result from increased diagnosis and life expec-
tancy and may relate to changing diet, lifestyle and
environmental factors.
For such a common tumour, it is absolutely remarkable
that so little is known about its molecular origins. The
expression of the p21 protein product of the ras oncogene as
assessed by immunohistochemistry has been found to distin-
guish between carcinoma and benign hypertrophy. Twenty
three of 29 cancers but none of 19 benign hypertrophy
specimens expressed p21. The degree of positivity correlated
with differentiation (Viola et al., 1986). Ras oncogene muta-
tions are uncommon, and were described in only one of 24
tumours (Carter et al., 1990). C-myc transcript levels have
been shown to distinguish between prostatic cancer and
benign hypertrophy and are significantly higher in tumours
(Fleming et al., 1986). There is differential expression of
oncogenes in cell culture, in response to an altered hormonal
milieu: c-fos and Ha-ras mRNA levels dramatically decrease
with withdrawal of androgens without change in c-myc
mRNA (Rijinders et al., 1985).
There have been limited investigations into the importance
of growth factors and their receptors in prostatic cancer. A
human cell line has been shown to secrete transforming
growth factor alpha and epidermal growth factor (Mac-
Donald et al., 1990). Receptors for epidermal growth factor
have been demonstrated in 44 of 65 (68%) prostatic tumours
but only three of 52 (6%) benign hypertrophy specimens.
Positivity did not relate to tumour stage nor grade (Fowler et
al., 1988). Expression of epidermal growth factor receptor
mRNA is higher in carcinoma than in benign prostatic tissue
(Morris & Green Dodd, 1990).
Tumour suppressor genes are implicated in prostatic cancer.
Abnormal expression ofthe retinoblastoma gene product was
described in one of three human prostatic cancer cell lines.
Transfection of the normal retinoblastoma gene into this line
resulted in its decreased ability to form tumours in nude mice
(Bookstein et al., 1990). Ha-ras transfection has been shown
to increase metastatic potential (Treiger & Isaacs, 1988).
Steroid hormone receptors have been investigated in pros-
tatic cancer and androgen receptor positivity correlates better
with hormonal response than oestrogen receptor or pro-
gesterone receptor status (Trachtenberg & Walsh, 1982).
Recently, a new class of peptide receptor for gonado-
trophin releasing hormone together with its ligand has been
found in a human hormone sensitive prostatic cancer cell line
and tumour biopsy specimens and the receptor is not ex-
pressed in hormone insensitive cell lines although the ligand
is present (Qayum et al., 1990). This finding suggests a direct
effect of this group of compounds in carcinoma of the pros-
tate.
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Although endocrine therapies for prostatic cancer were
popularised in the 1940's (Huggins & Hodges, 1941), patients
with prostatic 'diseases' were treated by orchiectomy in the
1890's by W.H. White (1893). The first analyses of the effects
of treatment were published in the early 1950's and these
retrospective studies showed an advantage to hormonal
therapy (Nesbit & Baum, 1950). The first prospective ran-
domised studies were published in 1967 by the Veterans
Administration Cooperative Urological Research Group and
showed a similar overall survival in patients treated by
orchiectomy or placebo or patients receiving oestrogen
therapy or placebo (VACURG, 1967) (Blackard et al., 1973).
It later turned out that many of the patients who received
placebo therapy eventually were treated by their local
primary care physicians and the 'real' result of this investiga-
tion was to demonstrate that early as compared to delayed
treatment had the same result. This subject remains contro-
versial and is currently being investigated in an MRC study
which compares early with delayed treatment in asympto-
matic patients. The design of this trial has caused con-
siderable public controversy, which relates to its ethical basis.
It is questionable whether there is such a thing as asympto-
matic metastatic prostatic cancer. Many patients who have
minimal symptoms that they had that they thought were due
to arthritis or old age improve with treatment because these
symptoms were due to symptomatic bone metastases.
An even more important point arising from the Veterans
study was the observation of the cardiovascular toxicity of
oestrogen therapy. This considerable toxicity relates to the
effect of oestrogen treatment on platelet aggregation and
plasma volume and stimulated research into alternative
medical therapies for prostatic cancer. In order of their his-
torical development, cyproterone acetate, medroxypro-
gesterone acetate and flutamide have all been investigated
and as single agent treatments have either been found to be
less effective than conventional treatment, although this is
contentious, or to have side effects (Pavone-Macaluso et al.,
1986; Sogani et al., 1975).
The gonadotrophin releasing hormone agonists were intro-
duced into the treatment of prostatic cancer in the early
1980's. Their advantages are specificity and lack ofcardiovas-
cular toxicity (Waxman, 1987). The only side effect of
treatment is tumour flare and this can be avoided by the
concurrent use of antiandrogens (Waxman et al., 1988).
Treatment was initially given as daily subcutaneous injections
or five or six times daily nasal insufflations, but now is
available as once monthly depot preparations. Depot
preparations that can be given once every 2 or 3 months have
also been developed (Waxman et al., 1990), but their in-
troduction into clinical practice has been delayed because of
ligitation between major drug companies as to the ownership
of patients. Hopefully this will resolve and the potential
advantage to the patient of these long acting depots can then
be obtained.
In the mid 1980's a considerable furore developed over the
concept of 'total' androgen blockade. The basis for this
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hypothesis was that in a disease that is androgen sensitive it
is important to eliminate all sources of androgens. In a
normal male 95% of circulating androgens are of testicular
origin and only 5% of adrenal origin. However, in the
medically castrate male, up to 45% of tissue androgens may
be of adrenal origin. On this basis it was suggested that
treatment with an antiandrogen and gonadotrophin releasing
hormone agonist might be of advantage to the patient. How-
ever, the laboratory work and early clinical studies (Labrie et
al., 1987) supporting this hypothesis were received sceptically.
The interest in the idea was considerable, mainly patient
driven, and resulted in the organisation of a National Cancer
Institute based clinical trial comparing treatment with leupro-
lide and flutamide with leuprolide alone. Over 600 patients
were entered into this study which showed an advantage to
combination therapy both in terms of median time to pro-
gression which was 16 as compared to 14 months and
median survival which was 35 as compared with 28 months
(Crawford et al., 1989).
Despite this result, the controversy remains and at a recent
Congress, ten trials were reported which involved 3,447
patients. In not all of these studies was all of the appropriate
information available, however, in three of seven trials in
which objective response was described, there was an advant-
age to combination therapy, and in three of eight trials an
advantage in terms of median time to progression. In just
one of nine trials was there prolonged survival and this trial
was the NCI study (Beland et al., 1990; Mahler et al., 1990;
Bertagna et al., 1990; de Voogt, 1990; Boccardo, 1990; Craw-
ford et al., 1990; Ferrari et al., 1990; Haefliger, 1990; Iversen,
1990; 0. Fourcade, et al., 1990). So it would seem that the
issue is unresolved as to whether total androgen blockade is
of advantage in prostatic cancer. Regardless of the heat
generated by this particular controversy, the best that can be
expected as indicated by the NCI study, is an improvement
in survival of 7 months and this hardly has a major impact in
terms of the overall prospects for each individual patient with
cancer of the prostate. Are there other approaches? New
antiandrogens, have been developed, and these include
casodex and nilutamide, which may have a marginal
theoretical advantage over other antiandrogens (Lunglmayr,
1989; Neri & Kassem, 1984). There have been studies ofearly
chemotherapy given in the adjuvant setting and these have
shown at best a minimal gain (Osborne et al., 1990). The
major management problem in prostatic cancer is how to
deal with the patient with recurrent disease. In this situation
the prospects for the patient are poor with a median expecta-
tion of survival from symptomatic relapse ofjust 6 months.
Approximately 20% of patients will respond to further
endocrine therapy and cortisone acetate without aminog-
lutethimide is probably the most effective agent (Plowman et
al., 1987).
Perhaps it is cliched to state that further research into the
molecular basis for response and relapse in this tumour
group is necessary and that it is hoped that from this, new
treatment will develop, but it is extraordinary that so little is
being done to try and understand the molecular origins of
the second most common cause of cancer deaths in men in
the First and Second Worlds.
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